(12) **Translation of European patent specification**

(11) **NO/EP 3551627 B1**

NORWAY

(19) NO

(51) Int Cl.
C07D 413/14 (2006.01)
A61K 31/4439 (2006.01)
A61K 31/501 (2006.01)
A61P 25/28 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2022.04.19
(80)	Date of The European Patent Office Publication of the Granted Patent	2022.02.16
(86)	European Application Nr.	17816630.2
(86)	European Filing Date	2017.12.07
(87)	The European Application's Publication Date	2019.10.16
(30)	Priority	2016.12.08, EP, 16202889
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Validation States:	MA
(73)	Proprietor	F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Sveits
(72)	Inventor	BUETTELMANN, Bernd, c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124, 4070 Basel, Sveits CECERE, Giuseppe, c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124, 4070 Basel, Sveits FASCHING, Bernhard, c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124, 4070 Basel, Sveits GROEBKE ZBINDEN, Katrin, c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124, 4070 Basel, Sveits HERNANDEZ, Maria-Clemencia, c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124, 4070 Basel, Sveits KNUST, Henner, c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124, 4070 Basel, Sveits KOBLET, Andreas, c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124, 4070 Basel, Sveits PINARD, Emmanuel, c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124, 4070 Basel, Sveits THOMAS, Andrew, c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124, 4070 Basel, Sveits
(74)	Agent or Attorney	PLOUGMANN VINGTOFT, Postboks 1003 Sentrum, 0104 OSLO, Norge

(54) Title **NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM**

(56) References Cited:
WO-A1-2009/071476
WO-A1-2010/112475
WO-A1-2009/071477

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

PATENTKRAV

1. Forbindelser med formel (I),



(I)

hvori

X er valgt fra

i) N og

ii) CH;

Y er valgt fra

i) N og

ii) CR^{10};

Z er valgt fra

i) N og

ii) CR^{11};

R^1 er valgt fra

i) C_{1-6}-alkyl,

ii) halogen-C_{1-6}-alkyl,

iii) C_{1-6}-alkoksy,

iv) halogen-C_{1-6}-alkoksy,

v) hydroksy-C_{1-6}-alkyl,

vi) C_{3-8}-sykloalkyl,

vii) halogen og

viii) amino substituert på nitrogenatomet med én eller to substituenter uavhengig valgt fra

a. H,

b. C_{1-6}-alkyl og

c. C_{3-8}-sykloalkyl;

R^2 er valgt fra

i) H og

i) halogen;

R^3 er valgt fra

i) H,

ii) C_{1-6}-alkyl,

iii) C_{3-8}-sykloalkyl,

iv) hydroksy-C_{1-6}-alkyl og

v) halogen-C_{1-6}-alkyl;

R^4 er valgt fra

i) H,

ii) C_{1-6}-alkyl,

iii) C_{1-6}-alkoksy,

iv) C_{3-8}-sykloalkyl og

v) halogen;

R^5 er H;

R^6 er valgt fra

i) H,

i) C_{1-6}-alkyl,

ii) C_{3-8}-sykloalkyl substituert med R^7, R^8 og R^9,

iii) C_{3-8}-sykloalkyl-C_{1-6}-alkyl substituert med R^7, R^8 og R^9,

iv) C_{1-6}-alkylsulfonyl-C_{1-6}-alkyl,

v) cyano-C_{1-6}-alkyl,

vi) hydroksy-C_{1-6}-alkyl,

vii) dihydroksy-C_{1-6}-alkyl,

viii) halogen-C_{1-6}-alkyl,

ix) heterosykloalkyl substituert med R^7, R^8 og R^9 og

x) heterosykloalkyl-C_{1-6}-alkyl substituert med R^7, R^8 og R^9;

R^7, R^8 og R^9 er uavhengig valgt fra

i) H,

ii) C_{1-6}-alkyl,

iii) C_{1-6}-alkoksy,

iv) C_{1-6}-alkoksyalkyl,

v) C_{1-6}-alkoksykarbonyl,

vi) cyano,

vii) C_{3-8}-sykloalkoksy,

viii) C_{3-8}-sykloalkyl,

ix) halogen-C_{1-6}-alkoksy,

x) halogen-C_{1-6}-alkyl,

xi) halogen,

xii) hydroksy,

xiii) hydroksy-C_{1-6}-alkyl og

xiv) okso;

R^{10} er valgt fra

i) H,

ii) C_{1-6}-alkyl,

iii) C_{1-6}-alkoksy,

iv) C_{3-8}-sykloalkyl og

v) halogen;

R^{11} er valgt fra

i) H,

ii) C_{1-6}-alkyl,

iii) C_{1-6}-alkoksy,

iv) C_{3-8}-sykloalkyl og

v) halogen;

eller R^5 og R^{10} sammen danner $-(CH_2)_n-$;

eller R^5 og R^{11} sammen danner $-(CH_2)_n-$;

eller R^5 og R^6 sammen med nitrogenatomet som de er festet til, danner et heterosykloalkyl substituert med R^7, R^8 og R^9;

n er valgt fra 1 og 2;

eller farmasøytisk akseptable salter.

2. Forbindelse ifølge krav 1, hvori

X er valgt fra

i) N og

ii) CH;

Y er valgt fra

i) N og

ii) CR^{10};

Z er valgt fra

i) N og

ii) CR^{11};

R^1 er valgt fra

i) C_{1-6}-alkyl,

ii) halogen-C_{1-6}-alkyl,

iii) C_{1-6}-alkoksy,

iv) C_{3-8}-sykloalkyl,

v) halogen og

vi) amino substituert på nitrogenatomet med to uavhengig valgte C_{1-6}-alkyl;

R^2 er valgt fra

i) H,

ii) halogen;

R^3 er valgt fra

i) H,

ii) C_{1-6}-alkyl,

iii) C_{3-8}-sykloalkyl, og

iv) halogen-C_{1-6}-alkyl;

R^4 er valgt fra

i) H og

ii) C_{1-6}-alkyl;

R^5 er H;

R^6 er valgt fra

i) H,

ii) C_{1-6}-alkyl,

iii) C_{3-8}-sykloalkyl substituert med R^7, R^8 og R^9, hvori R^7, R^8 og R^9 er uavhengig valgt fra

a. H,

b. C_{1-6}-alkyl,

c. C_{1-6}-alkoksy,

d. C_{1-6}-alkoksyalkyl,

e. C_{1-6}-alkoksykarbonyl,

f. cyano,

g. C_{3-8}-sykloalkoksy,

h. halogen-C_{1-6}-alkoksy,

i. halogen-C_{1-6}-alkyl,

j. halogen,

k. hydroksy og

l. hydroksy-C_{1-6}-alkyl;

iv) C_{3-8}-sykloalkyl-C_{1-6}-alkyl substituert med R^7, R^8 og R^9, hvori R^7, R^8 og R^9 er uavhengig valgt fra

a. H,

b. C_{1-6}-alkyl,

c. C_{1-6}-alkoksy,

d. C_{1-6}-alkoksyalkyl,

e. C_{1-6}-alkoksykarbonyl,

f. cyano,

g. C_{3-8}-sykloalkoksy,

h. halogen-C_{1-6}-alkoksy,

i. halogen-C_{1-6}-alkyl,

j. halogen,

k. hydroksy og

l. hydroksy-C_{1-6}-alkyl;

v) C_{1-6}-alkylsulfonyl-C_{1-6}-alkyl,

vi) cyano-C_{1-6}-alkyl,

vii) dihydroksy-C_{1-6}-alkyl,

viii) halogen-C_{1-6}-alkyl,

ix) heterosykloalkyl substituert med R^7, R^8 og R^9, hvori R^7, R^8 og R^9 er uavhengig valgt fra

a. H,

b. C_{1-6}-alkyl,

c. hydroksy og

d. okso;

og hvori heterosykloalkylet er valgt fra

a. oksetanyl,

b. tetrahydrofuranyl,

c. tetrahydropyranyl,

d. oksepanyl,

e. oksabisyklo[2.2.1]heptanyl,

f. oksaspiro[3.3]heptanyl,

g. azetidinyl,

h. tetrahydrotiofenyl og

i. tetrahydrotiopyranyl; og

x) oksetanyl-C_{1-6}-alkyl substituert med R^7, R^8 og R^9, hvori R^7, R^8 og R^9 er uavhengig valgt fra

a. H,

b. hydroksy;

R^{10} er valgt fra

i) H og

ii) halogen;

R^{11} er valgt fra

i) H,

ii) C_{1-6}-alkyl og

iii) C_{1-6}-alkoksy;

eller R^5 og R^{10} sammen danner $-(CH_2)_n-$;

eller R^5 og R^{11} sammen danner $-(CH_2)_n-$;

eller R^5 og R^6 sammen med nitrogenatomet de er festet til, danner et heterosykloalkyl substituert med R^7, R^8 og R^9, hvori R^7, R^8 og R^9 er uavhengig valgt fra

a. H,

b. C_{1-6}-alkyl,

c. C_{1-6}-alkoksy,

d. cyano,

e. halogen,

f. hydroksy og

g. okso;

og hvori heterosykloalkylet er valgt fra

a. azetidinyl,

b. pyrrolidinyl,

c. piperidinyl,

d. morfolinyl,

e. tiomorfolinyl,

f. oksaazabisyklo[3.1.1]heptanyl,

g. oksaazabisyklo[2.2.1]heptanyl,

h. azaspiro[3.3]heptanyl,

i. oksaazaspiro[3.3]heptanyl,

j. tiaazaspiro[3.3]heptanyl;

n er 1;

eller farmasøytisk akseptable salter.

3. Forbindelse ifølge krav 1, hvori

X er valgt fra

i) N og

ii) CH;

Y er valgt fra

i) N og

ii) CR^{10};

Z er valgt fra

i) N og

ii) CR^{11};

R^1 er valgt fra

i) C_{1-6}-alkyl,

ii) halogen-C_{1-6}-alkyl,

iii) C_{1-6}-alkoksy,

iv) C_{3-8}-sykloalkyl,

v) halogen og

vi) amino substituert på nitrogenatomet med to uavhengig valgte C_{1-6}-alkyl;

R^2 er valgt fra

i) H,

ii) halogen;

R^3 er valgt fra

i) H,

ii) C_{1-6}-alkyl,

iii) C_{3-8}-sykloalkyl og

iv) halogen-C_{1-6}-alkyl;

R^4 er valgt fra

i) H og

ii) C_{1-6}-alkyl;

R^5 er H;

R^6 er valgt fra

i) H,

ii) C_{1-6}-alkyl,

iii) C_{3-8}-sykloalkyl substituert med R^7, R^8 og R^9, hvori R^7, R^8 og R^9 er uavhengig valgt fra

a. H,

b. C_{1-6}-alkyl,

c. C_{1-6}-alkoksy,

d. C_{1-6}-alkoksyalkyl,

e. C_{1-6}-alkoksykarbonyl,

f. cyano,

g. C_{3-8}-sykloalkoksy,

h. halogen-C_{1-6}-alkoksy,

i. halogen-C_{1-6}-alkyl,

j. halogen,

k. hydroksy og

l. hydroksy-C_{1-6}-alkyl;

iv) C_{3-8}-sykloalkyl-C_{1-6}-alkyl substituert med R^7, R^8 og R^9, hvori R^7, R^8 og R^9 er uavhengig valgt fra

a. H,

b. C_{1-6}-alkyl,

c. C_{1-6}-alkoksy,

d. C_{1-6}-alkoksyalkyl,

e. C_{1-6}-alkoksykarbonyl,

f. cyano,

g. C_{3-8}-sykloalkoksy,

h. halogen-C_{1-6}-alkoksy,

i. halogen-C_{1-6}-alkyl,

j. halogen,

k. hydroksy og

l. hydroksy-C_{1-6}-alkyl;

v) C_{1-6}-alkylsulfonyl-C_{1-6}-alkyl,

vi) cyano-C_{1-6}-alkyl,

vii) dihydroksy-C_{1-6}-alkyl,

viii) halogen-C_{1-6}-alkyl,

ix) heterosykloalkyl substituert med R^7, R^8 og R^9, hvori R^7, R^8 og R^9 er uavhengig valgt fra

a. H,

b. C_{1-6}-alkyl,

c. hydroksy og

d. okso;

og hvori heterosykloalkylet er valgt fra

a. oksetanyl,

b. tetrahydrofuranyl,

c. tetrahydropyranyl,

d. oksepanyl,

e. oksabisyklo[2.2.1]heptanyl,

f. oksaspiro[3.3]heptanyl,

g. azetidinyl,

h. tetrahydrotiofenyl og

i. tetrahydrotiopyranyl; og

x) oksetanyl-C_{1-6}-alkyl substituert med R^7, R^8 og R^9, hvori R^7, R^8 og R^9 er uavhengig valgt fra

a. H,

b. hydroksy;

R^{10} er valgt fra

i) H og

ii) halogen;

R^{11} er valgt fra

i) H,

ii) C_{1-6}-alkyl og

iii) C_{1-6}-alkoksy;

eller farmasøytisk akseptable salter.

4. Forbindelse ifølge krav 1, hvori

X er valgt fra

i) N og

ii) CH;

Y er valgt fra

i) N og

ii) CR^{10};

Z er CR^{11};

R^1 er C_{1-6}-alkyl;

R^2 er valgt fra

i) H,

ii) halogen;

R^3 er valgt fra

i) C_{1-6}-alkyl,

ii) C_{3-8}-sykloalkyl og

iii) halogen-C_{1-6}-alkyl;

R^4 er valgt fra

i) H og

ii) C_{1-6}-alkyl;

R^5 er H;

R^6 er valgt fra

i) C_{1-6}-alkyl,

ii) C_{3-8}-sykloalkyl substituert med R^7, R^8 og R^9, hvori R^7, R^8 og R^9 er uavhengig valgt fra

a. H,

b. C_{1-6}-alkyl,

c. C_{1-6}-alkoksyalkyl og

d. halogen-C_{1-6}-alkyl;

iii) hydroksy-C_{1-6}-alkyl,

iv) halogen-C_{1-6}-alkyl,

v) heterosykloalkyl substituert med R^7, R^8 og R^9, hvori R^7, R^8 og R^9 er uavhengig valgt fra

a. H og

b. C_{1-6}-alkyl;

og hvori heterosykloalkylet er valgt fra

a. oksetanyl,

b. tetrahydrofuranyl,

c. tetrahydropyranyl,

d. oksepanyl og

e. oksaspiro[3.3]heptanyl;

R^{10} er H;

R^{11} er H;

eller farmasøytisk akseptable salter.

5. Forbindelse ifølge krav 1, hvori

X er CH;

Y er N;

Z er CR^{11};

R^1 er C_{1-6}-alkyl;

R^2 er H;

R^3 er C_{1-6}-alkyl;

R^4 er H;

R^5 er H;

R^6 er heterosykloalkyl substituert med R^7, R^8 og R^9;

R^7, R^8 og R^9 er H;

R^{11} er H;

eller farmasøytisk akseptable salter.

6. Forbindelse ifølge krav 1, hvori

X er CH;

Y er N;

Z er CR^{11};

R^1 er C_{1-6}-alkyl;

R^2 er H;

R^3 er C_{1-6}-alkyl;

R^4 er H;

R^5 er H;

R^6 er tetrahydropyranyl substituert med R^7, R^8 og R^9;

R^7, R^8 og R^9 er H;

R^{11} er H;

eller farmasøytisk akseptable salter.

7. Forbindelse ifølge et hvilket som helst av kravene 1 til 6, valgt fra

6-((5-metyl-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)-N-tetrahydropyran-4-yl-pyridin-3-karboksamid;
N-(syklopropylmetyl)-6-((5-metyl-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)pyridin-3-karboksamid;
N-etyl-6-((5-metyl-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)pyridin-3-karboksamid;
N-((1S)-1-(hydroksymetyl)butyl)-6-((5-metyl-3-(6-rnetyl-3-pyridyl)isoksazol-4-yl)metoksy)pyridin-3-karboksamid;
6-((5-syklopropyl-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)-N-((1S)-1-(hydroksymetyl)butyl)pyridin-3-karboksamid;
6-((5-syklopropyl-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)-N-tetrahydropyran-4-yl-pyridin-3-karboksamid;
(S)-N-(1-hydroksypentan-2-yl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydro-2H-pyran-4-yl)pyridazin-3-karboksamid;
2-isobutyl-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-1H-pyrrolo[3,4-c]pyridin-3(2H)-on;
2-metyl-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-1H-pyrrolo[3,4-c]pyridin-3(2H)-on;
N-isobutyl-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)nikotinamid;
2-(2-hydroksyetyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-1H-pyrrolo[3,4-c]pyridin-3(2H)-on;
(S)-2-(1-hydroksypentan-2-yl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-1H-pyrrolo[3,4-c]pyridin-3(2H)-on;
(S)-N-(1-hydroksypentan-2-yl)-5-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyrazin-2-karboksamid;
5-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydro-2H-pyran-4-yl)pyrazin-2-karboksamid;
N-(1,1-dioksotiolan-3-yl)-6-((5-metyl-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)pyridin-3-karboksamid;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)nikotinamid;

6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-((3S)-1,1-dioksotiolan-3-yl)-6-((5-metyl-3-(6-metylpyridin-3-yl)-1,2-oksazol-4-yl)metoksy)pyridin-3-karboksamid;
N-((3R)-1,1-dioksotiolan-3-yl)-6-((5-metyl-3-(6-metylpyridin-3-yl)-1,2-oksazol-4-yl)metoksy)pyridin-3-karboksamid;
N-(1,1-dioksotian-4-yl)-6-((5-metyl-3-(6-metylpyridin-3-yl)-1,2-oksazol-4-yl)metoksy)pyridin-3-karboksamid;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-2-(tetrahydro-2H-pyran-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-on;
N-((1S,2R)-2-hydroksysykloheksyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-((1S,2S)-2-hydroksysykloheksyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-((1R,2R)-2-hydroksysykloheksyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-syklopropyl-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-((1R,2S)-2-hydroksysykloheksyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-((3S,4R)-3-hydroksytetrahydropyran-4-yl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-(2-hydroksyetyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-(1,1-dioksotian-4-yl)-6-((5-metyl-3-(6-metylpyridin-3-yl)-1,2-oksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-(syklopropylmetyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-(syklopropylmetyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-(2-cyanoetyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
(RS)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(1,1,1-trifluorpropan-2-yl)pyridazin-3-karboksamid;

6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(oksetan-3-yl)pyridazin-3-karboksamid;
(RS)-N-(1,1-dioksotiolan-3-yl)-6-((5-metyl-3-(6-metylpyridin-3-yl)-1,2-oksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-etyl-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-isopropyl-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-isobutyl-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(2,2,2-trifluoretyl)pyridazin-3-karboksamid;
N-tert-butyl-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-(3,3-difluorsyklobutyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-(4,4-difluorsykloheksyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
6-((3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)-N-tetrahydropyran-4-yl-pyridin-3-karboksamid;
(RS)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydrofuran-3-yl)pyridazin-3-karboksamid;
N-metyl-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
(3,3-difluorazetidin-1-yl)(6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-yl)metanon;
(3,3-difluorpyrrolidin-1-yl)(6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-yl)metanon;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-((3-metyloksetan-3-yl)metyl)pyridazin-3-karboksamid;
6-((5-metyl-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)-N-(oksetan-3-ylmetyl)pyridazin-3-karboksamid;
N-((3-hydroksyoksetan-3-yl)metyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;

6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-((3R,4R)-3-metyltetrahydropyran-4-yl)pyridazin-3-karboksamid;
(4,4-difluorpiperidin-1-yl)(6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-yl)metanon;
N-(1-(metoksymetyl)syklopropyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
(3-metoksyazetidin-1-yl)(6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-yl)metanon;
(3-hydroksy-3-metylazetidin-1-yl)(6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-yl)metanon;
azetidin-1-yl(6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-yl)metanon;
(RS)-N-(2,2-dimetyltetrahydropyran-4-yl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(1-(trifluormetyl)syklopropyl)pyridazin-3-karboksamid;
(6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-yl)(morfolino)metanon;
(6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-yl)(2-oksa-6-azaspiro[3.3]heptan-6-yl)metanon;
4-metyl-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydropyran-4-yl)pyridazin-3-karboksamid;
(6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-yl)(6-oksa-1-azaspiro[3.3]heptan-1-yl)metanon;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(1,1,1-trifluor-2-metylpropan-2-yl)pyridazin-3-karboksamid;
(3-fluorazetidin-1-yl)(6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-yl)metanon;
(3-hydroksyazetidin-1-yl)(6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-yl)metanon;
(3-fluor-3-metylazetidin-1-yl)(6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-yl)metanon;
etyl-1-(6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamido)syklopropankarboksylat;

N-(1-cyanosyklopropyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
5-metyl-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
5-metyl-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydropyran-4-yl)pyridazin-3-karboksamid;
N-(1,1-dioksotian-4-yl)-5-((5-metyl-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)pyrazin-2-karboksamid;
N-(2-hydroksy-1,1-dimetyl-etyl)-5-((5-metyl-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)pyrazin-2-karboksamid;
N-syklopropyl-5-((5-metyl-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)pyrazin-2-karboksamid;
(RS)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(3-metyltetrahydrofuran-3-yl)pyridazin-3-karboksamid;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(1-metylsyklopropyl)pyridazin-3-karboksamid;
5-((5-metyl-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)-N-(oksetan-3-yl)pyrazin-2-karboksamid;
5-((5-metyl-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)-N-(2,2,2-trifluoretyl)pyrazin-2-karboksamid;
N-(4-hydroksy-2-metylbutan-2-yl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(2-metyl-4-(metylsulfonyl)butan-2-yl)pyridazin-3-karboksamid;
(S)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(3-metyltetrahydrofuran-3-yl)pyridazin-3-karboksamid;
(R)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(3-metyltetrahydrofuran-3-yl)pyridazin-3-karboksamid;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(3-metyloksetan-3-yl)pyridazin-3-karboksamid;
1-(6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karbonyl)azetidin-3-karbonitril;
N-(1-(hydroksymetyl)syklopropyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;

N-(4,4-difluorsykloheksyl)-5-((5-metyl-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)pyrazin-2-karboksamid;
(S)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydrofuran-3-yl)pyridazin-3-karboksamid;
(S)-N-(1-cyanobutan-2-yl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
(R)-5-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydrofuran-3-yl)pyrazin-2-karboksamid;
N-(2-hydroksyetyl)-5-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyrazin-2-karboksamid;
2-(1,1-dioksotian-4-yl)-6-[[5-metyl-3-(6-metylpyridin-3-yl)-1,2-oksazol-4-yl]metoksy]-1H-pyrrolo[3,4-c]pyridin-3-on;
(S)-5-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydrofuran-3-yl)pyrazin-2-karboksamid;
2-((5-metyl-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)-6-tetrahydropyran-4-yl-7H-pyrrolo[3,4-b]pyridin-5-on;
N-(1,1-dioksotiolan-3-yl)-5-((5-metyl-3-(6-metylpyridin-3-yl)-1,2-oksazol-4-yl)metoksy)pyrazin-2-karboksamid;
N-(syklopropylmetyl)-5-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyrazin-2-karboksamid;
2-(4,4-difluorsykloheksyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-1H-pyrrolo[3,4-c]pyridin-3(2H)-on;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(4-metyltetrahydro-2H-pyran-4-yl)pyridazin-3-karboksamid;
(R)-5-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydro-2H-pyran-3-yl)pyrazin-2-karboksamid;
(R)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydropyran-3-yl)pyridazin-3-karboksamid;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(2-oksaspiro[3.3]heptan-6-yl)pyridazin-3-karboksamid;
5-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(2-oksaspiro[3.3]heptan-6-yl)pyrazin-2-karboksamid;
5-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-((cis)-4-(trifluormetyl)sykloheksyl)pyrazin-2-karboksamid;

(S)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydropyran-3-yl)pyridazin-3-karboksamid;
N-((cis)-4-hydroksy-4-metylsykloheksyl)-5-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyrazin-2-karboksamid;
N-((trans)-4-hydroksy-4-metylsykloheksyl)-5-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyrazin-2-karboksamid;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(4-metyltetrahydro-2H-pyran-4-yl)nikotinamid;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-2-(tetrahydro-2H-tiopyran-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-on;
6-((5-metyl-3-(6-metylpyridazin-3-yl)isoksazol-4-yl)metoksy)-N-tetrahydropyran-4-yl-pyridin-3-karboksamid;
N-((1S)-1-(hydroksymetyl)butyl)-6-((5-metyl-3-(6-metylpyridazin-3-yl)isoksazol-4-yl)metoksy)pyridin-3-karboksamid;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(4-metyltetrahydrotiopyran-4-yl)pyridazin-3-karboksamid;
N-(4-metyl-1,1-dioksidotetrahydro-2H-tiopyran-4-yl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
(2,2-dioksido-2-tia-6-azaspiro[3.3]heptan-6-yl)(6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-yl)metanon;
(2,2-dioksido-2-tia-6-azaspiro[3.3]heptan-6-yl)(5-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyrazin-2-yl)metanon;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(1-metylsyklopentyl)pyridazin-3-karboksamid;
5-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(4,4,4-trifluorbutyl)pyrazin-2-karboksamid;
N-(1-isopropylazetidin-3-yl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-2-(2-oksaspiro[3.3]heptan-6-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-on;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(1-metylsyklobutyl)pyridazin-3-karboksamid;
6-((5-etyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydro-2H-pyran-4-yl)nikotinamid;

N-(1,1-dioksidotetrahydro-2H-tiopyran-4-yl)-6-((5-etyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)nikotinamid;
6-((5-etyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydropyran-4-yl)pyridazin-3-karboksamid;
6-((5-etyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(3-metyloksetan-3-yl)pyridazin-3-karboksamid;
N-syklopropyl-6-((5-etyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
(R)-N-(1-hydroksypentan-2-yl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)nikotinamid;
6-((5-(difluormetyl)-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)-N-((1S)-1-(hydroksymetyl)butyl)pyridin-3-karboksamid;
6-((5-(difluormetyl)-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)-N-tetrahydropyran-4-yl-pyridin-3-karboksamid;
N-((3R,4S)-3-hydroksytetrahydropyran-4-yl)-6-((5-metyl-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)pyridin-3-karboksamid;
6-((3-(6-syklopropyl-3-pyridyl)-5-metyl-isoksazol-4-yl)metoksy)-N-tetrahydropyran-4-yl-pyridin-3-karboksamid;
6-((3-(6-syklopropyl-3-pyridyl)-5-metyl-isoksazol-4-yl)metoksy)-N-((1S)-1-(hydroksymetyl)butyl)pyridin-3-karboksamid;
6-((3-(6-syklopropyl-3-pyridyl)-5-metyl-isoksazol-4-yl)metoksy)-N-(1,1-dioksotian-4-yl)pyridin-3-karboksamid;
N-((1R,2S)-3,3-difluor-2-hydroksysykloheksyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)nikotinamid;
N-((1R,2R)-2-hydroksysykloheksyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)nikotinamid;
N-((1S,2R)-3,3-difluor-2-hydroksysykloheksyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)nikotinamid;
N-((3S,4R)-3-hydroksytetrahydro-2H-pyran-4-yl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)nikotinamid;
N-((1S,2S)-2-hydroksysykloheksyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)nikotinamid;
2-fluor-N-metyl-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)nikotinamid;

6-((3-(6-metoksypyridin-3-yl)-5-metylisoksazol-4-yl)metoksy)-N-(tetrahydro-2H-pyran-4-yl)nikotinamid;
N-isopropyl-6-((3-(6-metoksypyridin-3-yl)-5-metylisoksazol-4-yl)metoksy)nikotinamid;
(S)-N-(1-hydroksypentan-2-yl)-6-((3-(6-metoksypyridin-3-yl)-5-metylisoksazol-4-yl)metoksy)nikotinamid;
(1,1-dioksidotiomorfolino)(6-((3-(6-metoksypyridin-3-yl)-5-metylisoksazol-4-yl)metoksy)pyridin-3-yl)metanon;
(S)-6-((3-(6-(dimetylamino)pyridin-3-yl)-5-metylisoksazol-4-yl)metoksy)-N-(1-hydroksypentan-2-yl)nikotinamid;
4-metoksy-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydro-2H-pyran-4-yl)nikotinamid;
6-((3-(5-fluor-6-metyl-3-pyridyl)-5-metyl-isoksazol-4-yl)metoksy)-N-tetrahydropyran-4-yl-pyridin-3-karboksamid;
6((3-(5-fluor-6-metyl-3-pyridyl)-5-metyl-isoksazol-4-yl)metoksy)-N-isopropyl-pyridin-3-karboksamid;
6-((3-(5-fluor-6-metyl-3-pyridyl)-5-metyl-isoksazol-4-yl)metoksy)-N-((1S)-1-(hydroksymetyl)butyl)pyridin-3-karboksamid;
N-((1r,4r)-4-hydroksy-4-metylsykloheksyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-(1,3-dihydroksy-2-metylpropan-2-yl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-((1s,4s)-4-hydroksy-4-metylsykloheksyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-((1R,3S)-3-hydroksy-3-(trifluormetyl)syklopentyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-((1S,3R)-3-hydroksy-3-(trifluormetyl)syklopentyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
(1S,4S)-2-oksa-5-azabisyklo[2.2.1]heptan-5-yl(6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-yl)metanon;
N-((1RS,3RS)-3-hydroksysyklopentyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
trans-N-(4-hydroksysykloheksyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;

trans-N-(4-metoksysykloheksyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
(6,6-difluor-2-azaspiro[3,3]heptan-2-yl)(6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-yl)metanon;
N-(3-hydroksysykloheksyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
3-oksa-6-azabisyklo[3.1.1]heptan-6-yl(6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-yl)metanon;
cis-N-(4-metoksysykloheksyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
6-((3-(6-klorpyridin-3-yl)-5-metylisoksazol-4-yl)metoksy)-N-(tetrahydro-2H-pyran-4-yl)pyridazin-3-karboksamid;
(S)-6-((3-(6-klorpyridin-3-yl)-5-metylisoksazol-4-yl)metoksy)-N-(tetrahydro furan-3-yl)pyridazin-3-karboksamid;
6-((3-(6-klorpyridin-3-yl)-5-metylisoksazol-4-yl)metoksy)-N-(3-metyloksetan-3-yl)pyridazin-3-karboksamid;
6-((3-(6-klorpyridin-3-yl)-5-metylisoksazol-4-yl)metoksy)-N-(2-oksaspiro[3.3]heptan-6-yl)pyridazin-3-karboksamid;
trans-N-(3-metoksysyklobutyl)-6-((5-metyl-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
cis-N-(3-metoksysyklobutyl)-6-((5-metyl-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
6-((5-syklopropyl-3-(6-metylpyridazin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydro-2H-pyran-4-yl)pyridazin-3-karboksamid;
trans-N-((1RS,3RS)-3-metoksysyklopentyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-(6,6-difluorspiro[3.3]heptan-2-yl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
6-((5-(fluormetyl)-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydropyran-4-yl)pyridazin-3-karboksamid;
cis-N-3-((2,2-difluoretoksy)syklobutyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
trans-N-3-((2,2-difluoretoksy)syklobutyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;

cis-N-(3-etoksysyklobutyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
trans-N-(3-etoksysyklobutyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
cis-N-(3-(difluormetoksy)syklobutyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
trans-N-(3-(difluormetoksy)syklobutyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
trans-N-(3-syklopropoksysyklobutyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
cis-N-(3-syklopropoksysyklobutyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
6-((3-(6-klorpyridin-3-yl)-5-syklopropylisoksazol-4-yl)metoksy)-N-(3-metyloksetan-3-yl)pyridazin-3-karboksamid;
6-((3-(6-klorpyridin-3-yl)-5-syklopropylisoksazol-4-yl)metoksy)-N-(2-oksaspiro[3.3]heptan-6-yl)pyridazin-3-karboksamid;
(S)-6-((3-(6-klorpyridin-3-yl)-5-syklopropylisoksazol-4-yl)metoksy)-N-(tetrahydrofuran-3-yl)pyridazin-3-karboksamid;
6-((5-syklopropyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(3-metyloksetan-3-yl)pyridazin-3-karboksamid;
6-((5-syklopropyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(2-oksaspiro[3.3]heptan-6-yl)pyridazin-3-karboksamid;
(S)-6-((5-syklopropyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydrofuran-3-yl)pyridazin-3-karboksamid;
6-((5-syklopropyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydropyran-4-yl)pyridazin-3-karboksamid;
6-((5-(fluormetyl)-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(1-(trifluormetyl)syklopropyl)pyridazin-3-karboksamid;
6-((5-metyl-3-(6-(trifluormetyl)pyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydropyran-4-yl)pyridazin-3-karboksamid;
N-((2S)-7-oksabisyklo[2.2.1]heptan-2-yl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
(RS)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(oksepan-4-yl)pyridazin-3-karboksamid;

6-((5-metyl-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)-N-((1R,3S,4R)-7-oksabisyklo[2.2.1]heptan-3-yl)pyridazin-3-karboksamid;
N-((2R)-7-oksabisyklo[2.2.1]heptan-2-yl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-((1R,3R)-3-etoksysyklopentyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-((1R,3R)-3-(2,2-difluoretoksy)syklopentyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
6-((5-(fluormetyl)-3-(6-metylpyridazin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydro-2H-pyran-4-yl)pyridazin-3-karboksamid;
6-((5-metyl-3-(6-metylpyridazin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydro-2H-pyran-4-yl)pyridazin-3-karboksamid;
N-[4-(2,2-difluoretoksy)sykloheksyl]-6-[[5-metyl-3-(6-metylpyridin-3-yl)-1,2-oksazol-4-yl]metoksy]pyridazin-3-karboksamid;
N-(4-etoksysykloheksyl)-6-[[5-metyl-3-(6-metylpyridin-3-yl)-1,2-oksazol-4-yl]metoksy]pyridazin-3-karboksamid;
eller farmasøytisk akseptable salter.

8. Forbindelse ifølge et hvilket som helst av kravene 1 til 7, valgt fra
N-((1S)-1-(hydroksymetyl)butyl)-6-((5-metyl-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)pyridin-3-karboksamid;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydro-2H-pyran-4-yl)pyridazin-3-karboksamid;
N-syklopropyl-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
(RS)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(1,1,1-trifluorpropan-2-yl)pyridazin-3-karboksamid;
N-isopropyl-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-tert-butyl-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
N-(1-(metoksymetyl)syklopropyl)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)pyridazin-3-karboksamid;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(1-(trifluormetyl)syklopropyl)pyridazin-3-karboksamid;

5-metyl-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydropyran-4-yl)pyridazin-3-karboksamid;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(1-metylsyklopropyl)pyridazin-3-karboksamid;
(S)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(3-metyltetrahydrofuran-3-yl)pyridazin-3-karboksamid;
(R)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(3-metyltetrahydrofuran-3-yl)pyridazin-3-karboksamid;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(3-metyloksetan-3-yl)pyridazin-3-karboksamid;
(S)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydrofuran-3-yl)pyridazin-3-karboksamid;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(4-metyltetrahydro-2H-pyran-4-yl)pyridazin-3-karboksamid;
(R)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydropyran-3-yl)pyridazin-3-karboksamid;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(2-oksaspiro[3.3]heptan-6-yl)pyridazin-3-karboksamid;
6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(1-metylsyklobutyl)pyridazin-3-karboksamid;
6-((3-(5-fluor-6-metyl-3-pyridyl)-5-metyl-isoksazol-4-yl)metoksy)-N-((1S)-1-(hydroksymetyl)butyl)pyridin-3-karboksamid;
6-((5-syklopropyl-3-(6-metylpyridazin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydro-2H-pyran-4-yl)pyridazin-3-karboksamid;
6-((5-(fluormetyl)-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydropyran-4-yl)pyridazin-3-karboksamid;
6-((5-syklopropyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(3-metyloksetan-3-yl)pyridazin-3-karboksamid;
(RS)-6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(oksepan-4-yl)pyridazin-3-karboksamid;
6-((5-(fluormetyl)-3-(6-metylpyridazin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydro-2H-pyran-4-yl)pyridazin-3-karboksamid;
6-((5-metyl-3-(6-metylpyridazin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydro-2H-pyran-4-yl)pyridazin-3-karboksamid;

eller farmasøytisk akseptable salter.

9. Forbindelse ifølge et hvilket som helst av kravene 1 til 8, hvori forbindelsen er 6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydro-2H-pyran-4-yl)pyridazin-3-karboksamid, som har den følgende strukturen



eller farmasøytisk akseptable salter.

10. Forbindelse ifølge krav 9, hvori forbindelsen er 6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydro-2H-pyran-4-yl)pyridazin-3-karboksamid.

11. Forbindelse ifølge krav 9, hvori forbindelsen er et farmasøytisk akseptabelt salt av 6-((5-metyl-3-(6-metylpyridin-3-yl)isoksazol-4-yl)metoksy)-N-(tetrahydro-2H-pyran-4-yl)pyridazin-3-karboksamid.

12. Forbindelse ifølge et hvilket som helst av kravene 1 til 8, hvori forbindelsen er N-((1S)-1-(hydroksymetyl)butyl)-6-((5-metyl-3-(6-metyl-3-pyridyl)isoksazol-4-yl)metoksy)pyridin-3-karboksamid, som har den følgende strukturen



eller farmasøytisk akseptable salter.

13. Forbindelse ifølge et hvilket som helst av kravene 1 til 12, for anvendelse som terapeutisk aktivt stoff.

14. Farmasøytisk sammensetning som omfatter en forbindelse ifølge et hvilket som helst av kravene 1 til 12, og en terapeutisk inert bærer.

15. Forbindelse ifølge et hvilket som helst av kravene 1 til 12, for anvendelse

i behandling eller forebygging av Alzheimers sykdom, lett kognitiv svekkelse, aldersrelatert kognitiv svikt, negative og/eller kognitive symptomer assosiert med schizofreni, bipolare lidelser, autismespekterforstyrrelse, Angelmans syndrom, Retts syndrom, Prader-Willis syndrom, epilepsi, posttraumatisk stresslidelse, amyotrofisk lateral sklerose, fragilt X-syndrom.